Prime Nr

Manremyc S.L. operates as a biotechnology firm spun out of the Germans Trias i Pujol Research Institute (IGTP) in 2013. The company was founded by a team that includes Dr. Pere-Joan Cardona, Dr. Cris Vilaplana, and Jaume Amat, leveraging over two decades of research from the IGTP's Experimental Tuberculosis Unit. Dr. Cardona, a physician specializing in microbiology, has dedicated his career since 1997 to understanding tuberculosis, which led to the discoveries underpinning Manremyc's core technology.

The company's primary focus is the development and commercialization of a food supplement named Nyaditum resae®. This product is a preparation containing heat-inactivated *Mycobacterium manresensis*, a non-pathogenic bacterium discovered in the Cardener River in Spain. The underlying principle of the product is to modulate the body's immune response to reduce the risk of latent tuberculosis infection progressing to active disease. It functions by inducing an immune tolerance, which helps prevent the excessive and damaging inflammation associated with active TB.

Nyaditum resae® is administered orally in capsules over a 14-day period. As a heat-killed preparation, it is classified as a food supplement, which simplifies the regulatory pathway compared to a live probiotic or vaccine. The company's business model is centered on sublicensing the technology to global partners in the probiotic and pharmaceutical markets for distribution. Distribution agreements are reportedly in place for numerous countries, with a strategic goal of making the supplement available for less than five euros per treatment course in regions with high tuberculosis prevalence.

Manremyc has secured its intellectual property with patents in multiple countries and has optimized the industrial manufacturing process for its core product. The company has engaged in multiple clinical trials to demonstrate the safety and immunogenicity of Nyaditum resae® in humans. Beyond tuberculosis, the immunomodulatory properties of *M. manresensis* have been explored for other applications, including a clinical trial to assess its potential in providing some protection against SARS-CoV-2 infection for healthcare workers. In 2019, the company launched a crowdfunding campaign through Capital Cell to raise €250,000 to further its clinical trials and commercialization efforts. Keywords: Manremyc, Nyaditum resae, Mycobacterium manresensis, tuberculosis supplement, immune modulation, Pere-Joan Cardona, IGTP spin-off, heat-killed probiotic, postbiotic, latent TB, tuberculosis prevention, food supplement, Reig Jofre, Germans Trias i Pujol Research Institute, Cris Vilaplana, Jaume Amat, clinical microbiology, immunogenicity, paraprobiotic, biotech, Badalona Spain